|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUDT15 |
Gene summary for NUDT15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUDT15 | Gene ID | 55270 |
| Gene name | nudix hydrolase 15 | |
| Gene Alias | MTH2 | |
| Cytomap | 13q14.2 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q9NV35 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55270 | NUDT15 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.09e-02 | 1.92e-01 | -0.0811 |
| 55270 | NUDT15 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.03e-06 | 2.49e-01 | -0.1088 |
| 55270 | NUDT15 | HTA11_347_2000001011 | Human | Colorectum | AD | 9.65e-12 | 3.20e-01 | -0.1954 |
| 55270 | NUDT15 | HTA11_83_2000001011 | Human | Colorectum | SER | 7.73e-08 | 3.31e-01 | -0.1526 |
| 55270 | NUDT15 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.75e-05 | 2.34e-01 | -0.1464 |
| 55270 | NUDT15 | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.65e-05 | 2.52e-01 | -0.059 |
| 55270 | NUDT15 | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.11e-02 | 2.42e-01 | -0.0179 |
| 55270 | NUDT15 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.25e-09 | 2.99e-01 | 0.294 |
| 55270 | NUDT15 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.60e-19 | 7.37e-01 | 0.281 |
| 55270 | NUDT15 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.39e-16 | 4.07e-01 | 0.3859 |
| 55270 | NUDT15 | LZE4T | Human | Esophagus | ESCC | 2.97e-03 | 4.65e-02 | 0.0811 |
| 55270 | NUDT15 | LZE5T | Human | Esophagus | ESCC | 2.02e-02 | 2.16e-01 | 0.0514 |
| 55270 | NUDT15 | LZE7T | Human | Esophagus | ESCC | 1.11e-02 | 1.55e-01 | 0.0667 |
| 55270 | NUDT15 | LZE8T | Human | Esophagus | ESCC | 1.75e-02 | 1.60e-01 | 0.067 |
| 55270 | NUDT15 | LZE20T | Human | Esophagus | ESCC | 2.60e-07 | 1.46e-01 | 0.0662 |
| 55270 | NUDT15 | LZE22D1 | Human | Esophagus | HGIN | 3.43e-02 | 3.56e-02 | 0.0595 |
| 55270 | NUDT15 | LZE24T | Human | Esophagus | ESCC | 9.30e-03 | 2.02e-01 | 0.0596 |
| 55270 | NUDT15 | P2T-E | Human | Esophagus | ESCC | 9.16e-20 | 4.81e-01 | 0.1177 |
| 55270 | NUDT15 | P4T-E | Human | Esophagus | ESCC | 1.60e-07 | 2.17e-01 | 0.1323 |
| 55270 | NUDT15 | P5T-E | Human | Esophagus | ESCC | 1.88e-08 | 1.74e-01 | 0.1327 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
| GO:1903362 | Colorectum | AD | regulation of cellular protein catabolic process | 109/3918 | 255/18723 | 2.14e-15 | 6.08e-13 | 109 |
| GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
| GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
| GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
| GO:1903050 | Colorectum | AD | regulation of proteolysis involved in cellular protein catabolic process | 92/3918 | 221/18723 | 2.04e-12 | 3.19e-10 | 92 |
| GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
| GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
| GO:0061136 | Colorectum | AD | regulation of proteasomal protein catabolic process | 75/3918 | 187/18723 | 1.65e-09 | 1.20e-07 | 75 |
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
| GO:0009144 | Colorectum | AD | purine nucleoside triphosphate metabolic process | 43/3918 | 88/18723 | 5.05e-09 | 3.19e-07 | 43 |
| GO:0006979 | Colorectum | AD | response to oxidative stress | 145/3918 | 446/18723 | 5.16e-09 | 3.23e-07 | 145 |
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0009141 | Colorectum | AD | nucleoside triphosphate metabolic process | 48/3918 | 112/18723 | 1.27e-07 | 6.02e-06 | 48 |
| GO:0000302 | Colorectum | AD | response to reactive oxygen species | 78/3918 | 222/18723 | 6.17e-07 | 2.21e-05 | 78 |
| GO:0071496 | Colorectum | AD | cellular response to external stimulus | 94/3918 | 320/18723 | 1.98e-04 | 2.64e-03 | 94 |
| GO:0009410 | Colorectum | AD | response to xenobiotic stimulus | 128/3918 | 462/18723 | 2.69e-04 | 3.31e-03 | 128 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUDT15 | SNV | Missense_Mutation | novel | c.99N>T | p.Lys33Asn | p.K33N | Q9NV35 | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| NUDT15 | SNV | Missense_Mutation | rs773719265 | c.248C>A | p.Ser83Tyr | p.S83Y | Q9NV35 | protein_coding | deleterious(0.01) | possibly_damaging(0.744) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUDT15 | SNV | Missense_Mutation | c.274N>G | p.Tyr92Asp | p.Y92D | Q9NV35 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| NUDT15 | SNV | Missense_Mutation | rs773719265 | c.248C>A | p.Ser83Tyr | p.S83Y | Q9NV35 | protein_coding | deleterious(0.01) | possibly_damaging(0.744) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NUDT15 | SNV | Missense_Mutation | rs773719265 | c.248N>A | p.Ser83Tyr | p.S83Y | Q9NV35 | protein_coding | deleterious(0.01) | possibly_damaging(0.744) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| NUDT15 | SNV | Missense_Mutation | rs773719265 | c.248C>A | p.Ser83Tyr | p.S83Y | Q9NV35 | protein_coding | deleterious(0.01) | possibly_damaging(0.744) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUDT15 | SNV | Missense_Mutation | c.443C>A | p.Pro148Gln | p.P148Q | Q9NV35 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NUDT15 | SNV | Missense_Mutation | c.330N>T | p.Lys110Asn | p.K110N | Q9NV35 | protein_coding | tolerated(0.1) | benign(0.295) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| NUDT15 | SNV | Missense_Mutation | rs773719265 | c.248N>A | p.Ser83Tyr | p.S83Y | Q9NV35 | protein_coding | deleterious(0.01) | possibly_damaging(0.744) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NUDT15 | SNV | Missense_Mutation | c.291G>A | p.Met97Ile | p.M97I | Q9NV35 | protein_coding | deleterious(0.03) | possibly_damaging(0.505) | TCGA-FI-A2EW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatinum | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 55270 | NUDT15 | ENZYME, CLINICALLY ACTIONABLE | Mercaptopurine | MERCAPTOPURINE | ||
| 55270 | NUDT15 | ENZYME, CLINICALLY ACTIONABLE | AZATHIOPRINE | AZATHIOPRINE | 26878724 | |
| 55270 | NUDT15 | ENZYME, CLINICALLY ACTIONABLE | Thioguanine | THIOGUANINE | ||
| 55270 | NUDT15 | ENZYME, CLINICALLY ACTIONABLE | mercaptopurine | MERCAPTOPURINE | 27530327,26503813,28146264,27558924,29967377,30035323,29923122,28659275,27381176,26590936,27193222,26878724,30048756,28445187,26033531,27416873,26076924,27604507,26735160,27577869,30101994,27095468 | |
| 55270 | NUDT15 | ENZYME, CLINICALLY ACTIONABLE | MERCAPTOPURINE | MERCAPTOPURINE | 26878724 | |
| 55270 | NUDT15 | ENZYME, CLINICALLY ACTIONABLE | azathioprine | AZATHIOPRINE | 27530327,26503813,28146264,27558924,30035323,25108385,29923122,27381176,26590936,27193222,30048756,26033531,27416873,26076924,27604507,26735160,27577869,30101994,27095468 | |
| 55270 | NUDT15 | ENZYME, CLINICALLY ACTIONABLE | thioguanine | THIOGUANINE | 27530327 | |
| 55270 | NUDT15 | ENZYME, CLINICALLY ACTIONABLE | THIOGUANINE | THIOGUANINE | 26878724 | |
| 55270 | NUDT15 | ENZYME, CLINICALLY ACTIONABLE | Azathioprine | AZATHIOPRINE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |